MX2020010119A - Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. - Google Patents

Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.

Info

Publication number
MX2020010119A
MX2020010119A MX2020010119A MX2020010119A MX2020010119A MX 2020010119 A MX2020010119 A MX 2020010119A MX 2020010119 A MX2020010119 A MX 2020010119A MX 2020010119 A MX2020010119 A MX 2020010119A MX 2020010119 A MX2020010119 A MX 2020010119A
Authority
MX
Mexico
Prior art keywords
antibody
antigen
binding fragment
medical use
provides
Prior art date
Application number
MX2020010119A
Other languages
English (en)
Inventor
Guoqing Cao
Lianshan Zhang
Yan Fang
Zhen Yan
Ruijun Shi
Hao Huang
Jiahua Jiang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2020010119A publication Critical patent/MX2020010119A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención proporciona un anticuerpo anti-CD27, un fragmento de unión a antígeno del mismo y un uso médico del mismo; específicamente, la presente invención proporciona un anticuerpo humano que comprende la región CDR del anticuerpo anti-CD27, y una composición farmacéutica que comprende el anticuerpo anti-CD27 humano y un fragmento de unión a antígeno del mismo y un uso del mismo como fármaco contra el cáncer; en particular, la invención proporciona un anticuerpo anti-CD27 humano y un uso del mismo en la preparación de un fármaco para el tratamiento de enfermedades o trastornos mediados por CD27.
MX2020010119A 2018-03-28 2019-03-27 Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. MX2020010119A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810267050 2018-03-28
PCT/CN2019/079811 WO2019184935A1 (zh) 2018-03-28 2019-03-27 抗cd27抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
MX2020010119A true MX2020010119A (es) 2020-10-15

Family

ID=68062563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010119A MX2020010119A (es) 2018-03-28 2019-03-27 Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.

Country Status (12)

Country Link
US (1) US20210009706A1 (es)
EP (1) EP3778636A4 (es)
JP (1) JP2021519088A (es)
KR (1) KR20200138762A (es)
CN (1) CN111511767A (es)
AU (1) AU2019241240A1 (es)
BR (1) BR112020019647A2 (es)
CA (1) CA3094005A1 (es)
MX (1) MX2020010119A (es)
RU (1) RU2020133807A (es)
TW (1) TWI745670B (es)
WO (1) WO2019184935A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4288455A1 (en) 2021-02-03 2023-12-13 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023122337A1 (en) 2021-12-23 2023-06-29 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
CN117024596B (zh) * 2023-08-18 2024-02-27 镜像绮点(上海)细胞技术有限公司 肿瘤原代细胞特异性标记与活体成像

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0620894D0 (en) 2006-10-20 2006-11-29 Univ Southampton Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
CA2729567C (en) * 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
AU2016216524A1 (en) * 2010-04-13 2016-09-01 Celldex Therapeutics Inc. Antibodies that bind human CD27 and uses thereof
BR112012026227A2 (pt) * 2010-04-13 2020-08-04 Celldex Therapeutics, Inc. anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo
BR122020002414B1 (pt) * 2012-03-15 2022-03-03 Janssen Biotech, Inc Uso de anticorpos anti-cd27 humanos
EP3268037B1 (en) * 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
JP7014783B2 (ja) * 2016-09-29 2022-02-01 ジエンス ヘンルイ メデイシンカンパニー リミテッド 抗ｃｄ２７抗体、その抗原結合性フラグメント、およびそのものの医学的使用

Also Published As

Publication number Publication date
CA3094005A1 (en) 2019-10-03
EP3778636A1 (en) 2021-02-17
RU2020133807A (ru) 2022-04-28
WO2019184935A1 (zh) 2019-10-03
RU2020133807A3 (es) 2022-04-28
TW201942135A (zh) 2019-11-01
TWI745670B (zh) 2021-11-11
CN111511767A (zh) 2020-08-07
EP3778636A4 (en) 2021-06-09
BR112020019647A2 (pt) 2021-01-05
US20210009706A1 (en) 2021-01-14
KR20200138762A (ko) 2020-12-10
AU2019241240A1 (en) 2020-10-29
JP2021519088A (ja) 2021-08-10

Similar Documents

Publication Publication Date Title
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
CY1122245T1 (el) Pd-1 αντισωμα, θραυσμα δεσμευσης αντιγονου αυτου, και ιατρικη εφαρμογη αυτου
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
MX2020001187A (es) Composiciones y métodos para la administración de virus adenoasociados.
MX2021014960A (es) Conjugado de farmaco-anticuerpos anti-b7-h4 y uso medicinal del mismo.
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
MX2022002592A (es) Conjugado de anticuerpo-farmaco que comprende un anticuerpo contra el gen del receptor huerfano 1 similar a tirosina cinasa receptora (ror1) humano y uso para el mismo.
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
MX2021001143A (es) Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
MX2021011489A (es) Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
MX2021009041A (es) Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
PH12020551447A1 (en) Antibodies
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2022001841A (es) Anticuerpos contra ilt2 y uso de los mismos.
MX2019003779A (es) Uso médico de un conjugado anticuerpo anti-c-met-fármaco citotóxico.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2022001065A (es) Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
MX2021010766A (es) Anticuerpos que se unen a la proteína del gen 6 inducible por el factor de necrosis tumoral (tsg-6) y usos de estos.
MX2021008941A (es) Moduladores gpr35.
IL288636A (en) Dosage regimen and management for the treatment or prevention of c5-related diseases using the anti-c5 antibody crobalimab
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.